Single molecule counting (SMC™) technology enables accurate measurement of molecules at levels previously undetectable allowing researchers to identify new biomarkers, or assist in therapeutic development with an improved view of efficacy, safety & time course studies. Combining a traditional immunoassay workflow with patented SMC™ technology enables the detection of low-abundance biomarkers, such as proteins and nucleic acids, with unparalleled sensitivity and accuracy, capturing concentrations down to the femtogram/mL level. You will learn how to detect, and monitor changes in, extremely low levels of established disease biomarkers such as cardiac troponin I and cytokines.
Anitaben Tailor, Ph.D
SMC™ Technology and Advanced Application Lead
Anitaben Tailor earned her MSc in pharmacology from King’s College London and her Ph.D. in biochemical pharmacology from Queen Mary University of London. Prior to joining Merck, she worked as a Field Application Scientist for Singulex for 5 years, where she provided Scientific support to Pharma and CRO’s on the SMC™ Technology. She then joined Merck in July 2015, and in 2016 was appointed the role of SMC™ Technology and Application Advancement Lead. She is responsible developing novel applications utilizing the on the SMC™ Technology for diverse research areas.
Research and disease areas